Healthcare Reform
Drug Reimbursement and the "New Medicaid"
A lot has been written about the "state option" created by the Supreme Court ruling on HCR, and what it means to American medicine. Sorting out an opinion will, to a degree, depend on whom you read and what you believe, writes Tom Norton
...Read more
Advertisement
Pharmaceutical companies are effecting a paradigm shift in their focus towards emerging markets driven by the growing economies of these markets and the steady decline of growth opportunities in the developed markets. Varied demography, varied government spending on health and differences in the regulatory environments in individual countries of the emerging markets require global pharmaceutical companies to create and implement specific and custom strategies to succeed in these markets.
The whitepaper examines the current trends, requirements and outsourcing solutions for effective medical communication approach for the emerging markets.  www.sciformix.com/ROI.php |
Washington Report
Fleshing Out the Safety and Innovation Act
There was much back-slapping on Capitol Hill in late June, as leading legislators reached across party lines to quickly approve the Food and Drug Administration Safety and Innovation Act (FDASIA). The bill enables FDA to collect some $6 billion in fees over the next five years from pharma and medical device companies, and, writes Jill Wechsler, it's much cleaner than the 2007 user-fee measure
...Read More
Advertisement
Remember When Pharmaceutical Marketing Was Relatively Simple?
Between physicians, patients, pharmaceutical companies, pharmacists, marketing managers, payors and the FDA, the conversation isn't so simple anymore. Are current communications meeting the needs of all these stakeholders? Is there a fix? What's ahead? Find out how our industry's conversation has changed direction and scope, and if we have the tools to deal with this dynamic challenge.
See what pharmaceutical marketing expert Al Topin has to say on the subject in his insightful article and his video presentation.  Learn More
|
Global
Japanese Pharma "Makes a Comeback"
After a series of government reforms that are appealing to both domestic and foreign players, the Japanese pharmaceutical market is making a comeback, writes Jane Wan ...Read More
Advertisement
The Impact of Comparative Effectiveness Research on the Healthcare Community
Live Webcast: Wednesday, August 29, 2012 at 11:00 AM Eastern
Register Free at  http://www.pharmexec.com/comparative
|
Medical Education
New Approaches to Medical Education Planning
A sweeping change has overtaken the way promotional medical education teams tackle planning. We're now seeing some exciting trends, writes Wendy Balter ...Read more
Advertisement
Path to Zero Landfill: Learn How One Company is Leading the Way
Live Webcast: Tuesday, August 21, 2012, 11:00 am EDT
Register Free at  www.pharmtech.com/landfill
|
|
|
|
 // Antares Pharma (Ewing, NJ) appointed Dr Jonathan Jaffe as VP of Clinical Development to head the company's progress in self-injection products and topical gel-based medicines. // Pfizer appointed Aijaz Tobaccowalla to lead its Mumbai-headquartered Indian operations, taking over from Kewal Handa who retires this month. // Dr Margaret Chan will serve a second term as Director General of The World Health Organization (WHO). Her role now extends to June 30, 2017. // Shire (Dublin, Ireland) made two senior promotions, David Colpman to lead its global business development team and elevating Ann Judge to its leadership team. |
|
